GSK plc (NYSE:GSK) Stock Holdings Increased by Concurrent Investment Advisors LLC

Concurrent Investment Advisors LLC increased its holdings in GSK plc (NYSE:GSK) by 16.3% during the second quarter, Holdings Channel reports. The firm owned 11,889 shares of the pharmaceutical company’s stock after purchasing an additional 1,663 shares during the period. Concurrent Investment Advisors LLC’s holdings in GSK were worth $458,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Register Financial Advisors LLC acquired a new stake in shares of GSK during the first quarter valued at approximately $31,000. Richardson Financial Services Inc. acquired a new stake in shares of GSK during the fourth quarter valued at approximately $40,000. Newbridge Financial Services Group Inc. acquired a new stake in shares of GSK during the first quarter valued at approximately $49,000. Triad Wealth Partners LLC acquired a new stake in shares of GSK during the second quarter valued at approximately $49,000. Finally, Jones Financial Companies Lllp raised its holdings in shares of GSK by 23.1% during the fourth quarter. Jones Financial Companies Lllp now owns 1,633 shares of the pharmaceutical company’s stock valued at $61,000 after acquiring an additional 306 shares during the period. 15.74% of the stock is currently owned by institutional investors.

GSK Stock Performance

Shares of GSK opened at $43.44 on Wednesday. The company has a debt-to-equity ratio of 0.99, a quick ratio of 0.54 and a current ratio of 0.82. The company has a market capitalization of $90.03 billion, a PE ratio of 15.74, a PEG ratio of 1.42 and a beta of 0.64. GSK plc has a 52 week low of $33.67 and a 52 week high of $45.92. The company’s 50 day moving average price is $40.24 and its 200 day moving average price is $41.61.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 10th. Shareholders of record on Friday, August 16th will be given a $0.3843 dividend. This represents a $1.54 annualized dividend and a yield of 3.54%. This is an increase from GSK’s previous quarterly dividend of $0.38. The ex-dividend date of this dividend is Friday, August 16th. GSK’s payout ratio is currently 54.71%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on GSK shares. Barclays upgraded shares of GSK to a “hold” rating in a report on Tuesday, August 27th. Jefferies Financial Group boosted their price target on shares of GSK from $52.50 to $53.00 and gave the company a “buy” rating in a report on Tuesday, July 2nd. Argus raised shares of GSK to a “strong-buy” rating in a research report on Wednesday, August 7th. Berenberg Bank raised shares of GSK to a “strong-buy” rating in a research report on Thursday, June 20th. Finally, UBS Group downgraded shares of GSK from a “buy” rating to a “neutral” rating in a research report on Monday, July 8th. Four research analysts have rated the stock with a hold rating, two have issued a buy rating and four have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $50.00.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.